USE OF RANOLAZINE FOR TREATING PULMONARY HYPERTENSION
This disclosure relates generally to treating patients having pulmonary hypertension such as pulmonary arterial hypertension (PAH), or symptoms associated therewith, by administering a therapeutically effective amount of ranolazine or a salt or salts thereof to the patient.
1 . A method of treating or preventing pulmonary hypertension in a patient in need thereof, said method comprising administering to the patient a therapeutically amount of ranolazine or a salt or salts thereof.
2 . The method of claim 1 , wherein the pulmonary hypertension is pulmonary arterial hypertension (PAH).
3 . The method of claim 2 , wherein the pulmonary arterial hypertension is selected from idiopathic PAH, familial PAH, pulmonary veno-occlusive disease (PVOD), pulmonary capillary hemangiomatosis (PCH), persistent pulmonary hypertension of the newborn, or PAH associated with another disease or condition.
4 . The method of claim 1 , wherein the patient has symptoms comprising chest pain, exertional dyspnea, and/or fatigue.
5 . The method of claim 4 , wherein the patient has symptoms comprising chest pain.
6 . The method of claim 4 , wherein the patient has symptoms comprising exertional dyspnea.
7 . The method of claim 4 , wherein the patient has symptoms comprising fatigue.
8 . A method for improving right ventricle function in a patient suffering from pulmonary hypertension, comprising administering to the patient a therapeutically effective amount of ranolazine or a salt or salts thereof.
9 . A method for reducing pulmonary arterial pressure in a patient suffering from pulmonary hypertension, comprising administering to the patient a therapeutically effective amount of ranolazine or a salt or salts thereof.
10 . A method for treating or ameliorating a symptom in a patient suffering from pulmonary hypertension, comprising administering to the patient a therapeutically effective amount of ranolazine or a salt or salts thereof.
11 . The method of claim 10 , wherein the symptom comprises chest pain.
12 . The method of claim 10 , wherein the symptom comprises exertional dyspnea.
13 . The method of claim 10 , wherein the symptom comprises fatigue.
14 . A method of treating or preventing asymptomatic pulmonary hypertension in a patient in need thereof, said method comprising administering to the patient a therapeutically amount of ranolazine or a salt or salts thereof.
15 . The method of claim 14 , wherein the patient does not suffer from pain or chest pain.
16 . The method of any of claim 1 , 8 - 10 or 14 , wherein the ranolazine or the salt or salts thereof is administered intravenously.
17 . The method of any of claim 1 , 8 - 10 or 14 , wherein the ranolazine or the salt or salts thereof is administered orally.
18 . The method of any of claim 1 , 8 - 10 or 14 , wherein the ranolazine or the salt or salts thereof is administered in a sustained release formulation.
19 . The method of any of claim 1 , 8 - 10 or 14 , wherein the aggregate daily dose of ranolazine is about 3000 milligrams, 1500 milligrams, 1000 milligrams, 750 milligrams, 500 milligrams or 375 milligrams.
20 . A method of treating pulmonary arterial hypertension (PAH) in a patient in need thereof, said method comprising orally administering to the patient a therapeutically amount of ranolazine or a salt or salts thereof, wherein the therapeutically amount contains an aggregate daily dose of ranolazine in the amount of 75 milligrams, 500 milligrams or 375 milligrams.
21 . The method of any of claim 1 , 8 - 10 , 14 or 20 , wherein the patient is also administered an additional therapeutic agent selected from the group consisting of cardiac glycosides, vasodilators/calcium channel blockers, digoxin, an anticoagulant, a diuretic, prostacyclin, an endothelin receptor antagonist, and a phosphodiesterase inhibitor, or a combination thereof.
22 . The method of claim 21 , wherein the additional therapeutic agent is a vasodilators/calcium channel blockers.
23 . The method of claim 21 , wherein the additional agent is administered simultaneously with ranolazine or sequentially with ranolazine.
24 . The method of claim 23 , wherein when the additional agent is administered simultaneously, the agent and ranolazine are administered as a single dose.
25 . The method of claim 23 , wherein when the additional agent is administered simultaneously, the agent and ranolazine are administered as separate doses.
26 . The method of any of claim 1 , 8 - 10 , 14 or 20 , wherein the patient is further administered oxygen.